Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209014 | 0.88 | GPR119 (0.40) | ALDH1A1TSHRLMNAGAAGPR119 | |
| SCHEMBL22015110 | 0.88 | ALDH1A1 (0.36) | ALDH1A1TSHRLMNAGAAKMT2A | |
| SCHEMBL22015798 | 0.86 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNAGAAKMT2A | |
| SCHEMBL22015101 | 0.86 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNAGAAKMT2A | |
| SCHEMBL24208970 | 0.86 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNAGAAKMT2A | |
| SCHEMBL22015096 | 0.86 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNAGAAKMT2A | |
| SCHEMBL21963761 | 0.83 | ALDH1A1 (0.37) | ALDH1A1TSHRLMNAGAAKMT2A | |
| SCHEMBL21963853 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TSHRLMNAGAAKMT2A | |
| SCHEMBL28922630 | 0.75 | MAPT (0.33) | ALDH1A1TSHRLMNAGAAKMT2A | |
| SCHEMBL22015111 | 0.73 | ALDH1A1 (0.38) | ALDH1A1TSHRLMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| EP-3880664-A1 | LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | ALDH1A1 122/4885TSHR 3440/4885LMNA 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.